8T51 image
Deposition Date 2023-06-12
Release Date 2024-06-19
Last Version Date 2024-10-09
Entry Detail
PDB ID:
8T51
Title:
Crystal structure of Fab 3.10C2 bound to TREM2
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.90 Å
R-Value Free:
0.24
R-Value Work:
0.19
Space Group:
P 2 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:3.10C2 Fab heavy chain
Chain IDs:A, C
Chain Length:222
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:3.10C2 Fab light chain
Chain IDs:B, D
Chain Length:219
Number of Molecules:2
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Triggering receptor expressed on myeloid cells 2 peptide
Gene (Uniprot):TREM2
Chain IDs:E, F
Chain Length:20
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Rapid affinity optimization of an anti-TREM2 clinical lead antibody by cross-lineage immune repertoire mining.
Nat Commun 15 8382 8382 (2024)
PMID: 39333507 DOI: 10.1038/s41467-024-52442-y

Abstact

We describe a process for rapid antibody affinity optimization by repertoire mining to identify clones across B cell clonal lineages based on convergent immune responses where antigen-specific clones with the same heavy (VH) and light chain germline segment pairs, or parallel lineages, bind a single epitope on the antigen. We use this convergence framework to mine unique and distinct VH lineages from rat anti-triggering receptor on myeloid cells 2 (TREM2) antibody repertoire datasets with high diversity in the third complementarity-determining loop region (CDR H3) to further affinity-optimize a high-affinity agonistic anti-TREM2 antibody while retaining critical functional properties. Structural analyses confirm a nearly identical binding mode of anti-TREM2 variants with subtle but significant structural differences in the binding interface. Parallel lineage repertoire mining is uniquely tailored to rationally explore the large CDR H3 sequence space in antibody repertoires and can be easily and generally applied to antibodies discovered in vivo.

Legend

Protein

Chemical

Disease

Primary Citation of related structures